Enovis sold its diabetic footwear segment to focus on its core business, but its stock price remains low despite efforts to boost profitability. Analysts believe the company is undervalued, with a fair value estimate of $49.67. However, potential risks include technology delays and operational challenges.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing